<?xml version="1.0" encoding="utf-8"?>
    <rss version="2.0">
      <channel xmlns:content="http://purl.org/rss/1.0/modules/content/">
        <title>Experimental Biology and Medicine | Endocrinology and Nutrition section | New and Recent Articles</title>
        <link>https://www.ebm-journal.org/journals/experimental-biology-and-medicine/sections/endocrinology-and-nutrition</link>
        <description>RSS Feed for Endocrinology and Nutrition section in the Experimental Biology and Medicine journal | New and Recent Articles</description>
        <language>en-us</language>
        <generator>Frontiers Feed Generator,version:1</generator>
        <pubDate>2026-04-10T10:49:28.09+00:00</pubDate>
        <ttl>60</ttl>
        <item>
        <guid isPermaLink="true">https://www.ebm-journal.org/articles/10.3389/ebm.2026.10701</guid>
        <link>https://www.ebm-journal.org/articles/10.3389/ebm.2026.10701</link>
        <title><![CDATA[Ananalysis of the effects of Treg cell therapy intervention on the gut microbiota of type 1 diabetic mice using 16S rRNA gene sequencing]]></title>
        <pubdate>2026-03-03T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Mengyao Zhou</author><author>Kang Du</author><author>Hanmin Wang</author><author>Zhuxian Zhang</author><author>Rui Zhao</author><author>Chenghong Ma</author><author>Qionger Huang</author><author>Wei Zhang</author><author>Weiwen Chen</author>
        <description><![CDATA[This study established a type 1 diabetes (T1DM) mouse model via intraperitoneal injection of streptozotocin (STZ) and examined the effect of regulatory T (Treg) cells on the gut microbiota by comparing its composition and diversity across three groups: control, T1DM, and Treg-treated mice. Forty-one 8-week-old male C57BL/6 mice under specific pathogen-free conditions were divided into a healthy control group, an untreated T1DM group, and a Treg treatment group (receiving low, medium, or high doses). T1DM was induced by administering a low-dose STZ injection over five consecutive days, with diabetes confirmation defined as a blood glucose level ≥300 mg/dL. CD4+CD25+ Treg cells isolated from spleens of healthy mice were used for treatment. Fecal samples collected on days 0, 14, and 34 from three randomly selected mice per group were subjected to 16S rRNA gene sequencing targeting the V3-V4 regions. The results showed significant differences in both alpha and beta diversity among the groups. Dominant bacterial families varied: Ruminococcaceae and others were enriched in the Treg treatment group, Muribaculaceae in the control group, and Lactobacillaceae in the untreated T1DM group. Genus-level abundances also shifted over time. Firmicutes abundance positively correlated with Treg levels (r = 0.70, p = 0.0433) but negatively with IFN-γ, whereas Cyanobacteria exhibited the opposite correlation. The Firmicutes/Bacteroidetes ratio was higher in T1DM mice than in controls and lower in the Treg-treated group. Metabolic pathway analysis indicated that two-component systems and ABC transporters were more prevalent in T1DM mice. In summary, Treg cell treatment altered the diversity, composition, dominant taxa, and Firmicutes/Bacteroidetes ratio of the gut microbiota compared with untreated T1DM mice.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.ebm-journal.org/articles/10.3389/ebm.2025.10538</guid>
        <link>https://www.ebm-journal.org/articles/10.3389/ebm.2025.10538</link>
        <title><![CDATA[Selective association of plasma sphingolipid species with insulin sensitivity and secretion in normoglycemic Black and White American adults]]></title>
        <pubdate>2025-06-24T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Peace Asuzu</author><author>Naser Aliye Feto</author><author>Jim Wan</author><author>Frankie Stentz</author><author>Nawajes Mandal</author><author>Samuel Dagogo-Jack</author>
        <description><![CDATA[Ceramides and other sphingolipids are associated with diabetes risk. Here, we examined the association of plasma sphingolipids with insulin sensitivity and secretion in people without diabetes. We enrolled adults without diabetes based on 75-g oral glucose tolerance test. Assessments included clinical examination, insulin sensitivity (hyperinsulinemic euglycemic clamp), and insulin secretion (intravenous glucose tolerance test). Plasma levels of 58 sphingolipid species (including ceramides, monohexosylceramides, sphingomyelins, and sphingosine) were assayed using liquid chromatography tandem mass spectrometry. The study participants (N = 240; 129 Black, 111 White) had a mean age of 43.1 ± 12.0 y, body mass index (BMI) 29.4 ± 6.23 kg/m2, fasting plasma glucose 91.4 ± 6.91 mg/dL, and 2-h plasma glucose 123 ± 26.3 mg/dL. Several of the 58 SPLs species assayed showed variable associations with insulin sensitivity (r = 0.17–0.35, P = 0.039 - <0.0001) and secretion (r = 0.14–0.27; P = 0.038 - <0.0001). After correction for multiple testing, plasma levels of very-long-chain (VLC) monohexosylceramide C34:0 (r = 0.31 – 0.43, P < 0.0001) and VLC sphingomyelins C28-C34 (r = 0.31–0.35, P = 0.0004 - <0.0001) were significantly associated with insulin sensitivity. Plasma VLC sphingomyelin level were inversely associated with insulin secretion, plasma glucose, BMI, and waist circumference. We conclude that circulating VLC sphingomyelins are associated positively with insulin action and inversely with insulin secretion and adiposity in normoglycemic adults, indicating a possible link to glucoregulation that precedes the development of dysglycemia.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.ebm-journal.org/articles/10.3389/ebm.2025.10520</guid>
        <link>https://www.ebm-journal.org/articles/10.3389/ebm.2025.10520</link>
        <title><![CDATA[Alcohol consumption may not be a risk factor for sarcopenia in the older adults]]></title>
        <pubdate>2025-05-29T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>En-Hui Mao</author><author>Yun-Ling Bu</author><author>Qiao-Ling Liu</author><author>Jin-Shui Xu</author><author>Xiang Lu</author><author>Xi-Lan Yang</author><author>Wei Gao</author><author>Zheng-Kai Shen</author>
        <description><![CDATA[The relationship between drinking and sarcopenia remains controversial. The aim of the present study was to investigate the association of alcohol drinking with sarcopenia in the older adults. A prospective study with 5244 Chinese community-dwelling older adults aged ≥65 years was performed. Sarcopenia was assessed by appendicular skeletal muscle mass index, grip strength, and gait speed. A quantitative questionnaire was used to obtain the information of alcohol drinking. After 4-year follow-up, our study showed that drinkers had lower incidence of sarcopenia than those non-drinkers (19.4% vs. 30.4%, P < 0.001 in males and 9.5% vs. 20.4%, P = 0.004 in females, respectively). Moreover, male drinkers had higher levels of muscle mass [median (IQR): 7.3 (6.7–7.9) kg/m2 vs. 7.1 (6.5–7.7) kg/m2, P < 0.001] grip strength [median (IQR): 31.1 (26.5–35.0) kg vs. 29.6 (24.8–38.8) kg, P < 0.001], and gait speed [median (IQR): 1.08 (0.98–1.17) m/s vs. 1.05 (0.94–1.15) m/s, P < 0.001] than those non-drinkers, while female drinkers had higher gait speed [median (IQR): 1.02 (0.94–1.11) m/s vs. 0.99 (0.89–1.09) m/s, P = 0.031] than those non-drinkers. Multivariate logistic regression showed that in older adults younger than 85 years, both interim drinking (RR = 0.60; 95%CI = 0.39–0.93; P = 0.021 for males; RR = 0.36; 95%CI = 0.13–0.90; P = 0.035 for females) and daily drinking (RR = 0.78; 95%CI = 0.61–0.99; P = 0.045 for males; RR = 0.34; 95%CI = 0.12–0.96; P = 0.041 for females) were correlated with decreased risk of sarcopenia even after adjustment for confounding factors. However, our dose-response analysis did not show any significant relationship between daily alcohol intake and the risk of sarcopenia as well as the components of sarcopenia. In conclusion, our results indicated that alcohol drinking may not be a risk factor for sarcopenia in the older adults. Further research will help to understand the underlying mechanism of the observed causal relationship.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.ebm-journal.org/articles/10.3389/ebm.2025.10614</guid>
        <link>https://www.ebm-journal.org/articles/10.3389/ebm.2025.10614</link>
        <title><![CDATA[Erratum: Retraction: Pyridoxal 5′ phosphate protects islets against streptozotocin-induced beta-cell dysfunction – in vitro and in vivo]]></title>
        <pubdate>2025-04-24T00:00:00Z</pubdate>
        <category>Correction</category>
        <author>EBM Production Office </author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.ebm-journal.org/articles/10.3389/ebm.2024.10441</guid>
        <link>https://www.ebm-journal.org/articles/10.3389/ebm.2024.10441</link>
        <title><![CDATA[Retraction: Pyridoxal 5′ phosphate protects islets against streptozotocin-induced beta-cell dysfunction – in vitro and in vivo]]></title>
        <pubdate>2025-01-09T00:00:00Z</pubdate>
        <category>Retraction</category>
        <author>EBM Editorial Office </author>
        <description></description>
      </item><item>
        <guid isPermaLink="true">https://www.ebm-journal.org/articles/10.3389/ebm.2024.10240</guid>
        <link>https://www.ebm-journal.org/articles/10.3389/ebm.2024.10240</link>
        <title><![CDATA[Increased hip fracture risk in the patients with type 2 diabetes mellitus is correlated with urine albumin-to-creatinine ratio (ACR) and diabetes duration in men]]></title>
        <pubdate>2024-12-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Huiru Ding</author><author>Hongxia Wang</author><author>Guanghui Liu</author><author>Yu Wang</author><author>Dongxu Han</author><author>Xiaoya Zhang</author><author>Lige Song</author>
        <description><![CDATA[Patients with type 2 diabetes mellitus (T2DM) have increased hip fracture risk. And the association between urine albumin to creatinine ratio (ACR) and an increased risk of hip fracture in patients with T2DM remains controversial. This study aimed to investigate the association between urinary ACR and hip fracture risk in postmenopausal women and aged men with T2DM. The study included 219 postmenopausal women and 216 older men (mean age >60 years) with T2DM. Women and men were divided into control group (ACR<30 mg/g), microalbuminuria group (30 mg/g ≤ ACR<300 mg/g), and macroalbuminuria group (ACR≥300 mg/g) respectively. Demographic characteristics and clinical history were collected in patients. Biochemical indexes and bone turnover-related markers were measured in patients. In the study, we found that several factors, including age, T2DM duration, cerebral infarction history, serum corrected calcium levels and urine ACR were positively associated with hip fracture risk. However, 25-Hydroxyvitamin D and areal BMD were negatively associated with hip fracture risk. Furthermore, multiple regression analysis showed that urinary ACR level (β = 0.003, p = 0.044) and duration of T2DM (β = 0.015, p = 0.018) were positively and independently correlated with hip fracture risk in older men. In contrast, femoral neck BMD (β = −6.765, p < 0.001) was independently and negatively correlated with hip fracture risk in older men. This study indicated that the elevated ACR levels and longer T2DM duration were related to higher hip fracture risk in older men with T2DM, which could be beneficial for developing a predictive model for osteoporotic fractures in patients with type 2 diabetes in the future. However, results were inconsistent in women, hip fracture risk didn’t alter by changes in urinary microalbuminuria level in postmenopausal women with T2DM.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.ebm-journal.org/articles/10.3389/ebm.2024.10280</guid>
        <link>https://www.ebm-journal.org/articles/10.3389/ebm.2024.10280</link>
        <title><![CDATA[Berberine alleviates AGEs-induced ferroptosis by activating NRF2 in the skin of diabetic mice]]></title>
        <pubdate>2024-12-13T00:00:00Z</pubdate>
        <category>Original Research</category>
        <author>Chunjie Jiang</author><author>Guojuan Lao</author><author>Jianmin Ran</author><author>Ping Zhu</author>
        <description><![CDATA[Advanced glycation end products (AGEs) have adverse effects on the development of diabetic complications. Berberine (BBR), a natural alkaloid, has demonstrated its ability to promote the delayed healing of skin wounds. However, the impact of BBR on AGEs-induced ferroptosis in skin cells and the underlying molecular mechanisms remains unexplored. This study investigated the involvement of ferroptosis in AGEs-induced keratinocyte death, and the impact of BBR on ferroptosis in a db/db mouse model with long-term hyperglycemia was elucidated. A remarkable reduction in cell viability was observed along with increased malondialdehyde (MDA) production in AGEs-induced HaCaT cells. Intracellular reactive oxygen species (ROS) and iron levels were elevated in cells exposed to AGEs. Meanwhile, the protein expression of glutathione peroxidase 4 (GPX4) and ferritin light chain (FTL) was significantly decreased in AGEs-treated cells. However, pretreatment with BBR markedly protected cell viability and inhibited MDA levels, attenuating the intracellular ROS and iron levels and increased expression of GPX4 and FTL in vitro. Significantly diminished antiferroptotic effects of BBR on AGEs-treated keratinocytes were observed upon the knockdown of the nuclear factor E2–related factor 2 (NRF2) gene. In vivo, GPX4, FTL, and FTH expression in the epidermis of diabetic mice was significantly reduced, accompanied by enhanced lipid peroxidation. Treatment with BBR effectively rescued lipid peroxidation accumulation and upregulated GPX4, FTL, FTH, and NRF2 levels in diabetic skin. Collectively, the findings indicate that ferroptosis may play a significant role in AGEs-induced keratinocyte death. BBR protects diabetic keratinocytes against ferroptosis, partly by activating NRF2.]]></description>
      </item><item>
        <guid isPermaLink="true">https://www.ebm-journal.org/articles/10.3389/ebm.2024.10179</guid>
        <link>https://www.ebm-journal.org/articles/10.3389/ebm.2024.10179</link>
        <title><![CDATA[Corrigendum: Epigallocatechin gallate decreases plasma triglyceride, blood pressure, and serum kisspeptin in obese human subjects]]></title>
        <pubdate>2024-04-25T00:00:00Z</pubdate>
        <category>Correction</category>
        <author>Saimai Chatree</author><author>Chantacha Sitticharoon</author><author>Pailin Maikaew</author><author>Kitchaya Pongwattanapakin</author><author>Issarawan Keadkraichaiwat</author><author>Malika Churintaraphan</author><author>Chanakarn Sripong</author><author>Rungnapa Sririwichitchai</author><author>Sompol Tapechum</author>
        <description></description>
      </item>
      </channel>
    </rss>